Tests colchicine to see if atrial fibrillation returns after a heart rhythm shock
Tests colchicine against a placebo in adults with atrial fibrillation after cardioversion.
Plain-language title generated from the registry record
Registry title: Colchicine After Electrocardioversion for Atrial Fibrillation
Key facts
- Where
- Basel, Bern, Bruderholz, Lausanne, Lucerne, Olten, Rheinfelden, and Solothurn, SwitzerlandSee the 8 sites
- Phase
- Phase 3
Where in Switzerland
- University Hospital BaselBasel, SwitzerlandTaking people
- University Hospital BernBern, SwitzerlandTaking people
- Cantonal Hospital Baselland (KSBL)Bruderholz, SwitzerlandTaking people
- Lausanne University HospitalLausanne, SwitzerlandTaking people
- Lucerne Cantonal HospitalLucerne, SwitzerlandTaking people
- Cantonal Hospital OltenOlten, SwitzerlandTaking people
- Herzpraxis am RheinRheinfelden, SwitzerlandTaking people
- Solothurner Spitäler AGSolothurn, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT05890664EU 2024-516033-12-00
- Record updated
- 28 May 2025
- Original description
The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.Read full original descriptionShow less
Colchicine After Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial
The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.
Inclusion: Age \>18 years; ECG-documented AF prior to ECV; Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥30 minutes after ECV; Ability to give written informed consent.
Exclusion: Pulmonary vein isolation within 3 months prior to ECV or pulmonary vein isolation planned within 3 months after ECV; Intake of a strong inhibitor of CYP3A4 or P-Glycoprotein (clarithromycin, erythromycin, telithromycin, cyclosporine, ketoconazole or itraconazole); Known intolerance or hypersensitivity to Colchicine; Serious gastrointestinal disease (severe gastritis or diarrhea); Clinically overt hepatic disease; Significant immunosuppression (e.g. due to transplantation or rheumatic disease); Severe renal disease (eGFR\< 30ml/min/1.73m2); AF persistence after cardioversion or early AF recurrence within 30 minutes after ECV; Any other rhythm than AF before cardioversion; Any other absolute indication for Colchicine intake; Clinically significant blood dyscrasia (e.g., myelodysplasia); Pregnant or breastfeeding women, or women of child-bearing potential who do not use a highly effective form of birth control; Life expectancy \<1 year.